Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

315
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
315
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Liver Physiology01:30

Liver Physiology

4.1K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

327
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Adjuvant Interferon-β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study.

The Journal of dermatology·2026
Same author

Cutaneous Lesions of IgG4-related Disease.

Internal medicine (Tokyo, Japan)·2026
Same author

Efficacy of adjuvant anti-PD-1 antibody versus observation for resected nail apparatus melanoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma.

The British journal of dermatology·2025
Same author

Correlation Between Lymph Node Size and Radioisotope Uptake in Sentinel Nodes of the Popliteal and Inguinal Basins in Melanoma.

International journal of dermatology·2025
Same author

The Dermoscopic Findings in Merkel Cell Carcinoma in Japanese patients.

The Journal of dermatology·2025

Related Experiment Video

Updated: Mar 17, 2026

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

1.4K

[Iron and liver disease].

Koji Miyanishi, Junji Kato

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 27, 2016
    PubMed
    Summary

    Reducing iron in the liver helps combat oxidative stress and DNA damage, potentially improving conditions like nonalcoholic steatohepatitis (NASH). This therapy may reduce disease activity and prevent further cellular damage.

    Area of Science:

    • Hepatology
    • Oxidative Stress Research
    • Molecular Biology

    Background:

    • Free iron in the liver promotes reactive oxygen species (ROS) formation, leading to oxidative damage and collagen synthesis.
    • Hydroxyl radicals (*OH) generate promutagenic 8-hydroxy-2-deoxyguanosine (8-OHdG), indicating DNA damage.
    • Chronic hepatitis C patients benefit from iron reduction therapy, showing reduced hepatitis activity, fibrosis, and cancer.
    • Nonalcoholic steatohepatitis (NASH) livers exhibit increased hepatic iron and oxidative DNA damage.

    Purpose of the Study:

    • To investigate the role of hepatic iron accumulation in oxidative DNA damage in NASH.
    • To explore the potential therapeutic benefits of iron reduction therapy for NASH patients.

    Main Methods:

    • Analysis of hepatic iron levels and oxidative DNA damage markers in NASH livers.

    More Related Videos

    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
    08:45

    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

    Published on: May 10, 2022

    2.6K
    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
    05:08

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

    Published on: January 31, 2022

    5.7K

    Related Experiment Videos

    Last Updated: Mar 17, 2026

    Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
    07:32

    Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

    Published on: May 23, 2025

    1.4K
    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
    08:45

    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

    Published on: May 10, 2022

    2.6K
    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
    05:08

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

    Published on: January 31, 2022

    5.7K
  • Review of outcomes from iron reduction therapy in chronic hepatitis C and its potential application to NASH.

    • Main Results:

    • Hepatic iron accumulation and oxidative DNA damage are significantly increased in NASH livers.
    • Iron reduction therapy has shown efficacy in managing hepatitis, fibrosis, and hepatocarcinogenesis in other liver conditions.
    • NASH serum may contain factors that increase iron transporter DMT1 expression.

    Conclusions:

    • Iron reduction therapy presents a potential strategy to mitigate disease activity and hepatic oxidative damage in NASH.
    • Targeting iron accumulation could be a novel therapeutic approach for managing NASH progression and complications.